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ABSTRACT 
 
Background. Uraemic pruritus is the complaint most often found in patients with 
terminal renal failure (15-49 %) and hemodialysis patients (50-90%). Mikroinflamasi role 
as ferritin be one cause. Phototherapy NBUVB theoretically can lower serum ferritin, 
thereby reducing the intensity of pruritus in patients . 
Objective. The main objective to determine the effect of phototherapy NBUVB to 
decrease serum ferritin levels of uremic pruritus patients undergoing regular 
hemodialysis. The next goal NBUVB know the influence of phototherapy to decrease 
the intensity of itch (VAS). 
Methods. Quasi experimental with pre-post comparison design, comparing the 
reduction in serum ferritin levels before and after phototherapy NBUVB, here p < 0.05 
is said to be significant. 
Results. A total of 29 subjects who underwent the study protocol, 18 were male, the 
average age was 55.7 years, the largest cause of kidney disease is hypertension (48.3%), 
average 4.2 years old undergoing hemodialysis. There was a decrease which signifkan 
where median serum ferritin levels before phototherapy 1693 ng/mL (12.05 to 6000) and 
after phototherapy 275 ng/mL (12.55-6000) with p 0.001. The degree of intensity of 
pruritus also decreased significantly where the median VAS before phototherapy 7 (4-10) 
and after phototherapy 4 (2-8) with p 0.001. 
Conclusions. Phototherapy NBUVB lowering serum ferritin levels and degrees of 
intensity of pruritus (VAS) of uraemic pruritus in patients undergoing regular 
hemodialysis. 
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ABSTRAK 
Latar Belakang. Pruritus uremia merupakan keluhan yang paling sering ditemukan pada pasien 
gagal ginjal terminal (15-49%) dan pasien hemodialisis (50-90%). Peranan mikroinflamasi seperti 
feritin menjadi salah satu penyebabnya. Fototerapi NBUVB secara teori dapat menurunkan feritin 
serum sehingga mengurangi intensitas pruritus pada pasien pruritus uremia. 
Tujuan Penelitian. Tujuan utama untuk mengetahui pengaruh fototerapi NBUVB terhadap 
penurunan kadar feritin serum pasien pruritus uremia yang menjalani hemodialisis rutin. Tujuan 
sekunder untuk mengetahui pengaruh fototerapi NBUVB terhadap penurunan intesitas pruritus 
(VAS).  
Metode Penelitian. Kuasi eksperimental dengan desain pre post comparison, membandingkan 
penurunan kadar feritin serum sebelum dan sesudah fototerapi NBUVB, dan nilai p <0,05 
dikatakan bermakna. 
Hasil. Sebanyak 29 subyek yang menjalani protokol penelitian, 18 orang laki- laki, usia rerata 55,7 
tahun, penyebab gagal ginjal kronik terbanyak adalah hipertensi (48,3%), rerata lama menjalani 
hemodialisis 4,2 tahun. Terdapat penurunan kadar feritin serum yang signifkan dengan median sebelum 
fototerapi  1693 ng/mL (12,05-6000) dan setelah fototerapi 275 ng/mL (12,55-6000), nilai p  
0,001. Derajat intesitas pruritus (VAS) menurun signifikan dengan median sebelum fototerapi 7 (4-
10) dan setelah fototerapi 4 (2-8), nilai p 0,001. 
Simpulan. Fototerapi NBUVB menurunkan kadar feritin serum dan derajat intensitas pruritus 
(VAS) pada pasien pruritus uremia yang menjalani hemodialisis rutin. 
 
Kata kunci: GGK (Gagal Ginjal Kronik), Hemodialisis, Pruritus Uremia, Feritin Serum, Fototerapi 
NBUVB 
 
Introduction 
Uremic pruritus (PU) is the most 
common complaint in patients with 
terminal renal failure . Complaints 
significant pruritus was found in 15 % -
49 % of patients with chronic renal 
failure and 50 % -90 % in patients 
dialisis1 . A cross-sectional study that 
incorporates 18,000 hemodialysis 
patients , 42 % had moderate to severe 
pruritus, resulting in sleep disorders, 
depression, poor quality of life, and 
death1. 
Persistent microinflammation theories 
assume that inflammation may be 
related to the origin of the PU, such 
ferritin levels2,3,4.  
Phototherapy (FT) with broad band 
ultraviolet B (BBUVB) and narrow band 
ultraviolet B (NBUVB) showed effective 
results in the management of pruritus 
uremia4. NBU VB better than BBUVB 
because of the nature NBUVB more 
minimal in some risks, among others: 
eritemogenik, pruritogenik and 
karsinogenik5. FT NBUVB can 
selectively reduce the production of 
proinflammatory cytokines by cell T6. 
 
 
Methods 
The design used in this study is a quasi-
experimental design with pre - posttest 
comparison. The study compared 
reduction in serum ferritin levels before 
and after phototherapy NBUVB in 
patients with terminal renal failure 
undergoing regular hemodialysis 
suffering from uremic pruritus. 
This research was conducted in the 
Hemodialysis Installation Dr. Sardjito 
Hospital Yogyakarta from September to 
December 2013. The subjects in this 
study were patients with terminal renal 
failure undergoing regular hemodialysis 
at Dr. Sardjito Hospital Yogyakarta 
suffering from uraemic pruritus were 
willing to participate in research. 
The determination of the samples by the 
following formula: 
 
 
Information: 
n : The number of patient samples before 
and after phototherapy NBUVB 
Zα  : Type I error was set at 5 % , the 
hypothesis one direction, so Zα =1.64 
Zβ  : Error type II is set at 10 % , then Zβ 
= 1.28 
S:Standard deviations = 40 (taken from research 
Giovambattista et al., 2002) 
(X1 - X2) : Minimum considered significant 
difference = 25 (taken from research 
Giovambattista et al., 2002) 
So we get : 
n: 21, estimates that subjects who did not follow 
the protocol (drop out )  
20 % , the minimum sample size to 26 . 
 
The inclusion criteria study subjects (a) 
patients with terminal renal failure aged 
over 18 years who had undergone 
hemodialysis regularly for at least three 
months (b) complaints pruritus uremia 
minimum has lasted more than three 
months with a VAS score ≥ 4 and 
includes ≥ 36 % body area (c) the 
patient is willing to be included in the 
study and signed informed consent.The 
exclusion criteria for study subjects (a) 
found other systemic diseases such dr. 
Agus Siswanto, SpPD, K-Psi disease 
hepatobiliary, malignancy, and a history 
of atopy (b) there is a history of 
treatment imununosupresan in the last 3 
months (c) there is a history of skin 
diseases suffered today such as: 
psoriasis, dermatitis with variations, 
lichen simplex, and dermatophytosis (d) 
the conditions are active infection such 
as HIV (e) there is a history of 
antihistamine drug consumption and the 
use of emollients in the last one week. 
Instruments in this study (1) McGill 
Pain Questionnaire (MPQ) Indonesian 
version in which there are ratings Visual 
Analogue Scale to assess the degree of 
pruritus7 (2) devices phototherapy 
NBUVB Daavlin 24 lights Philips 
TL100W/ 01, Phototherapy with the 
initiation dose of 300 mJ/ cm2 for 5 
minutes which increased 10 % every 
subsequent phototherapy. Phototherapy 
is done 2 times a week for 4 weeks . The 
following lines of inquiry:
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Here are the basic characteristics of the subjects who participated in the study:
 Variable N (%) /mean + SD/median(min-max) 
Age (55.7 ± 9.4) 
Sex  
    Male 18 (62.07) 
    Female 11 (37.93) 
Caused Chronic Renal Failure  
    Diabetes  12 (41.39) 
    Hipertension 14 (48.28) 
    Urinary Tract Infection 1 (3.45) 
    Urinary Stone 1 (3.45) 
    Trauma 1 (3.45) 
Length of  hemodialysis (4.2 ± 3.8) 
Serum ferritin  levels before FT 1693 (12.05-6000) 
VAS before FT 7 (4-10) 
   
 
 
 
Fulfill MPQ Indonesian 
Version 
Measure Serum Feritin 
Levels 
 
Week IV 
HD 2x 
FT NBUVB 2x 
Week III 
HD 2x 
FT NBUVB 2x 
Chronic Renal Failure 
Reguler Hemodialysis 
Week I 
HD 2x 
FT NBUVB 2x 
 
Inclusion and 
Exclusion Criteria  
Week II 
HD 2x 
FT NBUVB 2x 
Fulfill MPQ Indonesian 
Version 
Measure Serum Feritin 
Levels 
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FT NBUVB influence on serum ferritin levels and VAS: 
 
Parameter       Before FT        After FT      p value 
Serum ferritin 
levels 
1693 (12.05-6000) 
275 (12.55-6000) 0.001 
VAS          7 ( 4-10)          4 (2-8)       0.001 
 
Results and Discussion 
Subjects who participated in this study 
of 35 people with 6 people of whom did 
not complete the entire study protocol/ 
drop out for various reasons, among 
others, issues of transport , there is no 
time for phototherapy, health conditions 
do not support phototherapy, and 
family factors subjects who did not 
supports phototherapy. 
Conclusions 
Phototherapy NBUVB lowering serum 
ferritin levels significantly in uremic 
pruritus patients undergoing routine 
hemodialysis. Phototherapy NBUVB 
was significantly lowered itch intensity 
in uremic pruritus patients undergoing 
routine hemodialysis. 
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